Home > Insider Trading > Filing (0000899243-16-025570)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1512762	Coherus Biosciences Inc.	CHRS	Biological Products, (No Disgnostic Substances) (2836)	273615821

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1622139	K. Peter Watler	C/O Coherus Biosciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City CA 94065	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2016-07-20	50,000	$2.08	50,000	No	4	M	Direct
Common Stock, $0.0001 Par Value	Disposition	2016-07-20	50,000	$25.02	0	No	4	S	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2016-07-20	23,741	$1.42	23,741	No	4	M	Indirect	By Wife
Common Stock, $0.0001 Par Value	Disposition	2016-07-20	23,741	$25.00	0	No	4	S	Indirect	By Wife

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	M	Indirect	By Wife
No	4	S	Indirect	By Wife

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2016-07-20	50,000	$0.00	50,000	$2.08
Common Stock	Stock Option (right to buy)	Disposition	2016-07-20	23,741	$0.00	23,741	$1.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
92,494		2022-12-13	No	4	M	Direct
16,247		2023-11-21	No	4	M	Indirect

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $25.00 to $25.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person's wife.
All shares underlying this option are vested and exercisable as of the date hereof.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from July 30, 2013, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.